BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies
NCT00207051
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
62
Enrollment
INDUSTRY
Sponsor class
Conditions
Colorectal Cancer
Interventions
DRUG:
Brivanib + Cetuximab
Sponsor
Bristol-Myers Squibb